CDK4/6 Inhibitors in Cancer: Efficacy, Resistance, and Combination Approaches
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 30 June 2026 | Viewed by 28
Special Issue Editor
Interests: CDK4/6 inhibitors in cancer therapy and natural aging; CDK4/6 inhibition in cellular senescence; sex disparity in CDK4/6 inhibition; cellular senescence and onco-geriatrics
Special Issue Information
Dear Colleagues,
CDK4/6 inhibitors (palbociclib, ribociclib, and abemaciclib) are currently approved by the U.S. FDA for the treatment of metastatic hormone receptor-positive, HER2-negative breast cancer in combination with endocrine therapies. In addition, numerous clinical trials are underway to evaluate their potential in other malignancies, such as melanoma, colorectal cancer, kidney cancer, and prostate cancer.
Although associated with certain side effects and toxicities, CDK4/6 inhibitors are generally better tolerated than conventional chemotherapies. Their demonstrated efficacy in combination strategies and potential role in the adjuvant setting make them both promising and, to some extent, groundbreaking in the landscape of cancer therapy. Therefore, comprehensive studies focusing on mechanistic insights, therapeutic efficacy, prognostic biomarkers and optimal combinations of CDK4/6 inhibitors are essential to maximize patient benefit.
I am pleased to invite you to contribute to this Special Issue, which aims to highlight recent advances in CDK4/6 inhibitors, with a focus on molecular mechanisms, therapeutic outcomes, drug resistance, potential biomarkers and combination strategies.
This Special Issue welcomes original research articles and reviews.
I look forward to your valuable contributions.
Dr. Boshi Wang
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- CDK4/6 inhibitors
- palbociclib
- abemaciclib
- ribociclib
- cancer
- senescence
- combinatorial therapy
- prognosis
- molecular mechanisms
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
